Acting CDC director blocks vaccine study, sparking criticism over scientific transparency
On April 10, the acting director of the Centers for Disease Control and Prevention halted publication of a CDC study that demonstrated benefits from COVID-19 vaccination, citing concerns about the study’s methodology. Public-health researchers and outside experts pushed back immediately, saying the study used a research design that has been standard in vaccine-effectiveness studies for decades.
Critics called the move highly unusual and warned it has practical consequences. Because CDC guidance and hospital protocols are often calibrated to published federal evidence, blocking the study removes data developed with federal resources from the public record and can impede clinical and policy decisions that depend on that evidence. Researchers noted that methodological disagreements are normally resolved through peer review rather than by preventing publication outright.
Observers also framed the decision as part of a broader pattern of the administration exercising tighter control over scientific information. The move drew comparisons to other recent disputes over data and information policy, including a March lawsuit from AI company Anthropic alleging government retaliation for refusing certain military uses of its technology. Critics say the acting CDC director did not propose an alternative review pathway to get the findings into the public domain.
The episode has renewed questions about who gets to decide what government agencies publish—an issue that resonates with ongoing federal efforts to deploy AI tools across agencies and with wider debates about transparency and governance. Democracy Now! first reported on the blocked study; crypto.news has been tracking the administration’s accelerated AI rollout and the attendant civil-liberties concerns.
Read more AI-generated news on: undefined/news
